Rana M. Abdelnaby

Dr. Rana M. Abdelnaby

Heliopolis University, Cairo, Al Qāhirah, Egypt
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Bioorganic Chemistry
Verified
Journal Article
Closed access
AHAmira A. Atef Ahmed Helwa
Amira A. Atef Ahmed Helwa
NENehad M. El-Dydamony
Nehad M. El-Dydamony
RRRasha A. Radwan
Rasha A. Radwan
SASahar M. Abdelraouf
Sahar M. Abdelraouf
RARana M. Abdelnaby
Rana M. Abdelnaby

2 June 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RARana M. Abdelnaby
Rana M. Abdelnaby
AEAfaf El-MalahMalah
Afaf El-MalahMalah
RMRasha Mohamed
Rasha Mohamed
MSMarwa Mohammed Saeed
Marwa Mohammed Saeed
RNRania I. Nadeem
Rania I. Nadeem
NENehad Mohamed Eldydamony
Nehad Mohamed Eldydamony
Protein kinases are seen as promising targets in controlling cell proliferation and survival in treating cancer where fused thiophene synthon was utilized in many kinase inhibitors approved by the FDA. Accordingly, this work focused on adopting fused thienopyrrole and pyrrolothienopyrimidine scaffolds in preparing new inhibitors, which were evaluated as antiproliferative agents in the HepG2 and PC-3 cell lines. The compounds 3b (IC50 = 3.105 and 2.15 μM) and 4c (IC50 = 3.023 and 3.12 μM) were the most promising candidates on both cells with good selective toxicity-sparing normal cells. A further mechanistic evaluation revealed promising kinase inhibitory activity, where 4c inhibited VEGFR-2 and AKT at IC50 = 0.075 and 4.60 μM, respectively, while 3b showed IC50 = 0.126 and 6.96 μM, respectively. Moreover, they resulted in S phase cell cycle arrest with subsequent caspase-3-induced apoptosis. Lastly, docking studies evaluated the binding patterns of these active derivatives and demonstrated a similar fitting pattern to the reference ligands inside the active sites of both VEGFR-2 and AKT (allosteric pocket) crystal structures. To conclude, these thiophene derivatives represent promising antiproliferative leads inhibiting both VEGFR-2 and AKT and inducing apoptosis in liver cell carcinoma.


17 August 2022 in New Journal of Chemistry
Verified
Journal Article
Closed access
PDF file
LGLina M. A. Abdel Ghany
Lina M. A. Abdel Ghany
NENehad M. El-Dydamony
Nehad M. El-Dydamony
AHAmira A. Atef Ahmed Helwa
Amira A. Atef Ahmed Helwa
SASahar M. Abdelraouf
Sahar M. Abdelraouf
RARana M. Abdelnaby
Rana M. Abdelnaby
The VEGFR-2/AKT pathway is a crucial axis in tumor survival where it is highly dysregulated in many cancer types. In this research, novel coumarin-acid hydrazides were synthesized and assayed for their anticancer activity in MCF-7 and Panc-1 cells via MTT assay where most compounds especially 4f and 4k showed promising antiproliferative activity with an IC50 of 0.73, 1.19 and 0.84, 3.61 μM against both cell lines, respectively. Their inhibitory activity on VEGFR-2/AKT-1 proteins was very promising with IC50 values of 0.18 and 0.12 μM on VEGFR-2 and 5.7 and 8.1 μM on AKT by 4f and 4k, respectively. Also, flow cytometry revealed cell cycle arrest with elevated caspase 8 and 9 levels leading to apoptosis by both compounds. Furthermore, docking studies revealed binding patterns similar to the reference ligands in VEGFR-2 and AKT-1 binding sites. Thus, these novel coumarin derivatives are promising anticancer leads via inhibiting the VEGFR-2/AKT axis and apoptosis induction.

31 March 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RARana M. Abdelnaby
Rana M. Abdelnaby
HRHeba Sayed Rateb
Heba Sayed Rateb
OAOmaima Ali
Omaima Ali
ASAhmed S. Saad
Ahmed S. Saad
RNRania I. Nadeem
Rania I. Nadeem
RARasha Abdelhady
Rasha Abdelhady
Breast cancer is the most common malignancy worldwide; therefore, the development of new anticancer agents is essential for improved tumor control. By adopting the pharmacophore hybridization approach, two series of 7-hydroxyl-4-methylcoumarin hybridized with thiosemicarbazone (V–VI) and thiazolidin-4-one moieties (VII–VIII) were prepared. The in vitro anticancer activity was assessed against MCF-7 cells adopting the MTT assay. Nine compounds showed significant cytotoxicity. The most promising compound, VIIb, induced remarkable cytotoxicity (IC50 of 1.03 + 0.05 µM). Further investigations were conducted to explore its pro-apoptotic activity demonstrating S-phase cell cycle arrest. Apoptosis rates following VIIb treatment revealed a 5-fold and 100-fold increase in early and late apoptotic cells, correspondingly. Moreover, our results showed caspase-9 dependent apoptosis induction as manifested by an 8-fold increase in caspase-9 level following VIIb treatment. Mechanistically, VIIb was found to target the PI3K-α/Akt-1 axis, as evidenced by enzyme inhibition assay results reporting significant inhibition of examined enzymes. These findings were confirmed by Western blot results indicating the ability of VIIb to repress levels of Cyclin D1, p-PI3K, and p-Akt. Furthermore, docking studies showed that VIIb has a binding affinity with the PI3K binding site higher than the original ligands X6K. Our results suggest that VIIb has pharmacological potential as a promising anti-cancer compound by the inhibition of the PI3K/Akt axis.

1 June 2014 in Bioorganic Chemistry
Verified
Journal Article
Closed access
DEDalal A. Abou El-Ella
Dalal A. Abou El-Ella
MHMohammed M. Hussein
Mohammed M. Hussein
RSRabah A.T. Serya
Rabah A.T. Serya
RARana M. Abdelnaby
Rana M. Abdelnaby
AAAhmed Al-Abd
Ahmed Al-Abd
KAKhaled A.M. Abouzid
Khaled A.M. Abouzid